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ABSTRACT 
Primary sclerosing cholangitis (PSC) is a chronic, inflammatory liver disease that leads to 
destruction of the bile duct system. PSC is strongly associated with inflammatory bowel 
disease, and PSC patients have an increased risk of developing malignancies, especially 
cholangiocarcinoma (CCA). The pathogenesis of PSC is still insufficiently understood, 
although T cells have been suggested to play a major role. Little is known about the 
involvement of other immune cell populations. In addition to this, a better understanding is 
needed about the capacity of liver resident immune cells to prevent tumor development. In 
this thesis we have investigated cellular and humoral components of the immune system, in 
PSC and the PSC-associated malignancy CCA. 
 In the first study, we examined the role of autoreactive antibodies in PSC 
patients. Flow cytometry was used to investigate the presence of IgA and IgG antibodies in 
PSC patient sera, and its reactivity against isolated human biliary epithelial cells. A majority 
of the patients had antibodies that bound to the cells, while only low levels could be detected 
in serum of healthy individuals. Moreover, IgA autoantibodies in PSC patients were 
associated with a reduced survival, and therefore their presence may be of importance in the 
pathogenesis of PSC. 
 In the second and third study, immunohistochemistry and image analysis was 
used, to explore the cell compositions in PSC and CCA livers. Specific phenotypic patterns, 
associated with severity of disease, were revealed in PSC livers. T cells were enriched, 
mainly localizing to fibrotic fields, whereas MAIT cells were not equally increased. 
Furthermore, one group of PSC patients, characterized by a potential loss of smooth muscle 
cell function, was found to have increased numbers of T cells and a more extensive bile duct 
proliferation. The tumor microenvironment in CCA was characterized by a selective loss of 
Kupffer cells and MAIT cells, and contained high numbers of regulatory T cells. Moreover, 
the expression of IL-33 was significantly lower in tumors. This distinct intratumoral 
phenotype was unaffected by tumor location, tumor differentiation, or an underlying PSC. 
 Altogether, our studies provide insights into the pathogenesis of PSC and CCA 
and opens up for further studies of disease mechanisms. 
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1 INTRODUCTION 
 
1.1 IMMUNOLOGY 
The immune system is under constant selection, to provide us protection against pathogenic 
microorganisms in the environment. The ability to distinguish self from non-self is one of the 
most critical challenges for the immune system to overcome, in order to mobilize a proper 
response against invading pathogens. The initial response is generated by cellular 
components of the innate immune system, such as neutrophils, monocytes, macrophages, 
complement, cytokines, and acute phase proteins. This is a highly conserved system between 
species, and crucial for the ability of the individual to survive. Innate immune cells recognize 
and bind to microbial structures, termed pathogen-associated molecular patterns (PAMPS). 
The binding initiates effector functions of the cells, such as phagocytosis, opsonization, and 
complement-mediated lysis, leading to the elimination of the pathogen. In addition to the 
innate immune system, higher animals have evolved an adaptive immune system. This 
system is highly specific, but often require days or weeks before it is fully activated (1). B 
and T cells, which are the main actors of the adaptive system, develop from progenitor cells 
in the bone marrow. At an early stage during development, T cell precursors migrate to the 
thymus for further development, whereas B cells remain in the bone marrow. B and T 
lymphocytes acquire their antigen-specific receptors through complex gene rearrangements, 
which leads to a large pool of lymphocytes, estimated to contain over 108 unique T-cell 
receptors and 1010 antibody specificities.  B and T lymphocytes continuously circulate 
through secondary lymphoid organs, and upon antigen delivery by antigen presenting cells, 
they get activated and start to differentiate. Thereafter, T cells are able to home to the infected 
site, where they exert effector functions, and B cells release antibodies into blood and tissue 
fluids (1). For T cells to combat intracellular pathogens, it is not enough with the ability to 
recognize structures of the microbe. They must also recognize the cells that have been 
infected. For this reason, T cells have developed unique properties of recognition of antigens 
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in combination with self-molecules. They only recognize antigenic peptides bound to major 
histocompatibility complex (MHC) molecules. In humans, this complex is commonly 
referred to as HLA (human leukocyte antigen). MHC class I molecules bind to peptide 
fragments produced by the cell´s own machinery, which occurs when the cells are virus or 
tumor transformed. MHC class II molecules bind to antigenic peptides derived from the 
extracellular environment, taken up by phagocytosis by the cell. MHC class II is particularly 
expressed by professional antigen-presenting cells, whereas all nucleated cells express MHC 
class I. However, some pathogens have developed strategies to escape presentation by MHC 
molecules (2), and genes within the MHC region are under a constant selective pressure. 
Therefore, genes within the MHC locus are highly polymorphic, i.e., there are multiple 
variants of each gene. This can be both favorable and unfavorable for the individual, because 
some gene variants may contribute to susceptibility to autoimmune, infectious, or 
inflammatory diseases (3). 
 
1.1.1 Liver immunology 
The liver has unique immune properties, largely due to its anatomical position in the body. It 
has a dual blood supply, both from the systemic blood and the gastrointestinal tract. From an 
immunological perspective this is important, since it does not only receive oxygen-rich blood 
from the systemic circulation, but also nutrient and antigen-rich blood from the gut. The 
blood enters the liver mainly through the portal vein, and drains through a highly branched 
vascular system, called sinusoidal endothelium, before leaving the organ via the central veins. 
Liver sinusoids are composed of a layer of fenestrated liver sinusoidal endothelial cells 
(LSEC), which makes them permeable. A large amount of lymphocytes from the peripheral 
blood passes the LSECs every minute (4). Due to the small diameter of the vessels, the 
lymphocytes are in close contact with LSECs, and are easily able to extravasate through the 
fenestrated cell layer (5). The liver harbors approximately ten billion lymphocytes (6). These 
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include cells of both the innate and the adaptive immune system. There are also several 
different cell types in the liver with the capability to present antigens to circulating 
lymphocytes. These include LSECs, Kupffer cells, hepatic stellate cells, and dendritic cells 
(DCs).  
 
1.1.1.1 Liver sinusoidal endothelial cells 
Up to half of the non-parenchymal cells in the liver are comprised of LSECs. They differ 
from other vascular endothelial cells in the body, as they express receptors for both antigen 
uptake and antigen presentation, such as scavenger receptors and MHC class I and II (7, 8). 
These properties give them a unique role in liver immunology and tolerance, as will be 
discussed in more detail.  
 
1.1.1.2 Kupffer cells 
Kupffer cells are liver resident macrophages and constitute 1/5 of the non-parenchymal cells 
of the liver (7). They are strategically positioned in the sinusoids and constitute a first line of 
defense against invading microorganisms. One of the effector functions of Kupffer cells upon 
bacterial stimulation is the production of cytokines (8). Secreted cytokines influence and 
shape the further immune response. As an example, they can activate and induce the 
differentiation of natural killer (NK) cells by the release of interleukins (IL), such as IL-12 
and IL-18 (9).  
 
1.1.1.3 Natural killer cells 
NK cells are innate immune cells with cytotoxic activity against virus or tumor-transformed 
cells. They constitute about 30% of the total lymphocyte population in the liver, and are 
regulated by a balance of signals between activating and inhibitory receptors. The ligands for 
the inhibitory receptors on NK cells are MHC class I molecules, and as long as these are 
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expressed on the surface of nearby cells, NK cells are kept in an inactive state (10). Both the 
absence of MHC class I, as well as presence of activating signals, is required for the 
induction of NK cell cytotoxicity. Upon activation they release cytokines, such as interferon 
(IFN)-γ, which leads to the expression of chemokines by LSECs and recruitment of T cells 
(11). 
 
1.1.1.4 T cells 
The majority of lymphocytes in the liver consist of T cells. Cytotoxic T cells are 
characterized by the expression of the glycoprotein CD8 on the cell surface and thus, 
commonly referred to as CD8+ T cells. They are restricted to recognize peptide fragments in 
conjunction with MHC class I molecules, and are therefore key immune cells in the defense 
against virus and intracellular pathogens (12). CD8+ T cells are known to be more abundant 
in the liver than the CD4+ T cells (6), which constitute the second population of conventional 
T cells. They are characterized by the expression of CD4 on the cell surface and recognize 
antigens presented by MHC class II molecules. One of their main role is to help cytotoxic T 
cells to become fully activated (13). 
 
1.1.1.5 Mucosal-associated-invariant T cells 
Other T cell populations, with a more innate-like phenotype, such as mucosal-associated-
invariant T (MAIT) cells, are found at higher frequencies in the liver than in the peripheral 
blood (14). MAIT cells are characterized by the expression of a semi-invariant T cell receptor 
(TCR-Vα7.2) and respond to bacterial antigens, presented by the MHC-like molecule MR1, 
with immediate effector functions (15). 
1.1.1.6 B cells 
B cells are known to be scarce in the liver, and little is known about their immunological 
activities here (6). According to the classical model, activation and maturation of B cells 
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occur in secondary lymphoid organs (16) and at present, it is not known whether B cells can 
be primed in the liver. However, plasma cells (antibody-producing B cells) line the biliary 
epithelium in the liver, and by producing and secreting immunoglobulin (Ig) A antibodies 
into bile, they likely have a role in the protection of bile ducts against invading pathogen (17). 
Antibodies are components of the humoral immune response and offer protection against 
extracellular pathogens. They develop as membrane-bound receptors on B cells in the bone 
marrow, each one unique for its particular antigen. B cells migrate to secondary lymphoid 
organs, where they meet their specific antigen and start to mature with the help of 
costimulatory signals from CD4+ T helper cells. Upon activation, B cells start to differentiate 
and proliferate, and become either antibody-producing effector cells or memory B cells. 
Effector cell-released antibodies have the same antigen specificity as the initially produced 
membrane-bound antibodies (18).   
 
 
Copyright © 2006, Rights Managed by John Wiley and Sons 
Figure 1.1: The distribution of cells in the healthy liver. Percentages refer to estimated 
frequencies of the different cellular subsets in relation to the total number of liver cells. 
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1.2 LIVER STRUCTURE AND FUNCTION 
The liver is the largest gland in the body (19). It has many important roles in glucose, protein 
and lipid metabolism as well as functions in detoxification and removal of waste products 
(20). The microanatomical structure of the liver is divided into functional units, called liver 
lobules. Each liver lobule has a central vein in the middle, from which the functional liver 
cells, the hepatocytes, radiate to the portal tracts, also known as portal triads, in the periphery. 
Each portal triad consists of one hepatic artery, one hepatic portal vein and one common bile 
duct (21). 
Bile, which is produced by the hepatocytes, is transported via a complex network of bile 
conduits, lined by biliary epithelial cells (BECs), and finally converges into the common bile 
duct. From there it empties into the gall bladder before further secretion to the intestine. The 
major function of the BECs is to modify the bile before its secretion. These cells also 
constitute the main target cells in several cholestatic diseases, commonly referred to as 
cholangiopathies.  
 
 
Copyright © 2006, Rights Managed by John Wiley and Sons 
Figure 1.2: Schematic drawing of a portion of a liver lobule. To the left is the central vein, 
from which the hepatocytes radiate towards the periphery (to the right), where the portal 
triads are located. Each portal triad contains one hepartic artery, one portal vein, and one bile 
duct. Within the lumen of the sinusoidal endothelium, resident Kupffer cells patrol the area, 
whereas DCs mainly locate near the portal zones.  Immune cells, such as T cells and NK cells 
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arrive from the peripheral blood and flow within the sinusoids, in close contact with the 
LSECs.  
 
1.3 LIVER TOLERANCE 
The liver is constantly exposed to microbial products from the portal blood. For this reason, 
the liver has evolved unique immunosuppressive mechanisms, which together cooperate to 
keep the environment tolerogenic. LSECs have efficient scavenger functions, that keep the 
vessels clean from antigens and bacterial compounds (22), and they also have the capacity to 
present antigens to CD4+ and CD8+ T cells (23). However, under non-inflammatory 
conditions, these interactions fail to activate an immune response (24). Instead, tolerance is 
induced, as T cells start to secrete suppressive cytokines, such as IL-4 and IL-10 (25).  
Other resident liver cells, such as Kupffer cells, contribute to the tolerance as well. Under 
normal conditions, they do not get triggered by soluble antigens, since they do not express 
MHC class II or co-stimulatory molecules (26). Instead they interact with regulatory T cells 
(Tregs), which leads to more IL-10 production and, thus, an immunosuppressive environment 
(27). During inflammation in the liver, tolerance can be broken and Kupffer cells can get 
activated to induce T cell proliferation (28).  
 
1.3.1 Breaking of tolerance 
Immune tolerance can be broken if the liver is exposed to live bacteria, viruses, or increasing 
levels of PAMPs. This induces a robust inflammatory response, with recruitment of large 
numbers of lymphocytes from the peripheral blood to the liver (29). 
1.3.1.1 Liver inflammation 
Inflammation in the liver begins when a primary injury, caused by viral or bacterial attacks 
for example, initiates cell death of hepatocytes and /or BECs. The leakage of cellular contents 
into the local environment, and increased levels of reactive oxygen species (ROS), attracts 
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and activate Kupffer cells and hepatic stellate cells. These cells start to remove dying cells by 
phagocytosis. By doing so, they also secrete pro-inflammatory mediators, such as tumor 
necrosis factor (TNF), IL-6 and IL-1β, which in turn attract T cells and neutrophils to the site 
of injury. The recruitment of different cellular subsets further amplifies the inflammatory 
response, and secreted cytokines, in particular transforming growth factor beta (TGF-β), 
causes the transdifferentiation of hepatic stellate cells into myofibroblasts. When these cells 
mature and become fully activated, they start to produce extracellular matrix (ECM) proteins, 
which initiate the fibrotic process (30). 
 
1.3.1.2 Liver fibrosis 
Hepatic stellate cells normally reside as lipid and vitamin A-storing, quiescent cells, situated 
in the space of Disse, between the hepatocytes and sinusoidal endothelium. Upon liver injury, 
they change phenotype and start to proliferate, migrate and acquire contractile properties. 
Their full activation leads to the synthesis and secretion of extracellular matrix (ECM) 
proteins, especially type I collagen, as well as secretion of pro-fibrogenic factors, such as 
TGF-β (30). Macrophages are observed to localize in the vicinity of myofibroblasts in 
fibrotic livers and soluble mediators in the environment, such as monocyte chemoattractant 
protein-1 (MCP-1) and macrophage colony-stimulating factor (M-CSF), have been shown to 
prolong the activation state of myofibroblasts, suggesting an active cross-talk between these 
two cell types (31). 
Furthermore, the recruitment of T cells, and the balance between the differentiated subtypes 
of Th cells, Th1 and Th2 cells, has also been shown to be of importance for the fibrotic 
outcome. Th1 cytokines have been shown to be more prone to reduce fibrosis (32), whereas 
Th2 cytokines, such as IL-13 and IL-33, have pro-fibrogenic effects (33). Fibrosis is part of 
the healing process, and type I collagen has been shown to protect hepatocytes against toxic 
compounds (34). However, if tissue injury persists and the fibrotic process continues in a 
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dysregulated manner, clinical complications can arise (Figure 1.3). If the primary injury is 
eliminated, the liver tissue can regain its normal structure, since the fibrosis, in its early 
stages, is reversible. However, once cirrhosis is established, the process is in most cases 
irreversible. In advanced stages, when liver failure occurs, the only curative option is liver 
transplantation (30). 
 
 
Figure 1.3: Stages of chronic liver disease. Inflammation, caused by an initial injury leads to 
fibrosis development with deposition of scar matrix. This process is reversible, if the injury is 
healed. Continued inflammation leads to further increased fibrosis and eventually cirrhosis. 
Once cirrhosis is established, the possibility to reverse the process is decreased (30). 
 
1.4 BILIARY EPITHELIAL CELLS 
 
1.4.1 Physiological functions 
BECs constitute only about 4-5% of the total number of cells in the liver, but have many 
important physiologic and immunologic functions. Modification of bile is one of their major 
functions, and occurs by the secretion of ions, solutes and water into the bile duct lumen (35). 
This is a process tightly regulated by hormones, peptides and neurotransmitters. Another 
function is to secrete IgA into bile (36). This occurs via a mechanism where serum IgA first 
bind to the secretory component on the basolateral side of the biliary epithelium and 
thereafter get endocytosed and further transported via vesicles to the apical membrane. At 
this site, proteolytic cleavage of the secretory component takes place, which results in the 
release of IgA into bile (37). Since the distal part of the biliary system, the common bile duct, 
drains into the duodenum, secreted IgA has a crucial role in protecting the biliary tree against 
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gastrointestinal-derived pathogens. Main effector functions of IgA is to aggregate bacteria 
and prevent them from attaching to the mucous membranes, as well as protecting against 
intracellular pathogens during the transcytosis pathway, through the biliary epithelium (38). 
 
1.4.2 Activation of BECs 
In the healthy liver, BECs do not divide. As a response to biliary injury, however, they can 
start to proliferate and become immunologically active, a phenomenon known as ductular 
reaction. BECs express toll-like receptors (TLRs), which upon binding to pathogen-derived 
ligands start to synthesize IL-6, IL-1β and IL-23 (38). These cytokines mediate recruitment 
and differentiation of T cells. Recently, the differentiation of naive T cells into Th17 cells 
have been proposed to be of importance in the pathogenesis of chronic inflammatory 
diseases. Reactive BECs are also important players in fibrosis, since they produce pro-
inflammatory and profibrogenic cytokines, whose interactions lead to an exaggeration of the 
mesenchymal response, with further deposition of ECM proteins into the liver parenchyma. 
Furthermore, the release of IL-6 stimulates BECs in an autocrine fashion, thereby leading to a 
continued release of inflammatory mediators (38).  
 
1.5 PRIMARY SCLEROSING CHOLANGITIS 
PSC is a chronic, cholestatic liver disease that is characterized by inflammation, fibrosis and 
destruction of the intra- and/or extrahepatic bile ducts. This leads to development of cirrhosis 
and eventually liver failure. PSC is strongly associated with inflammatory bowel disease 
(IBD), especially ulcerative colitis (UC), which is present in up to 80% of the PSC patients in 
northern Europe (39). Based on population studies from Norway, Great Britain and United 
States, the prevalence of PSC is estimated to be 8.5-13.6/100 000, which is 10-100 times 
higher than in the southern parts of Europe and Asia (40). Two thirds of the patients are male 
and the median age at onset is 30-40 years (39). There are no effective medical treatments for 
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PSC, and more than half of the patients need a liver transplant within 10-15 years after the 
first symptoms. Although survival is increased after liver transplantation, one fifth of the 
patients are at risk of developing recurrent disease in the liver graft (40). There is also an 
increased risk for PSC patients to develop malignancies, particularly cholangiocarcinoma 
(CCA), which often has a poor outcome.  
 
1.5.1 Diagnosis 
PSC is often asymptomatic in its initial stage, and is usually detected first when the patient's 
liver enzymes increase. As the disease progresses, symptoms such as jaundice, pruritus and 
abdominal pain arise, accompanied by episodes of bacterial cholangitis, with fever and 
worsening of liver biochemistries. The diagnosis of PSC is based on a typical cholangiogram 
with multiple strictures and dilatations. Serum liver tests usually show increased liver 
enzymes, in particular alkaline phosphatase (ALP). The presence of autoantibodies is also 
common. A majority of the patients have a history of IBD and show signs of cholestasis. The 
use of magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde 
cholangiopancreatography (ERCP) is used to visualize the bile ducts (Figure 1.4). ERCP is 
reserved for patients with dominant strictures and who are in a need for biliary intervention 
(41).  
 
 
Copyright © 2010, Rights Managed by Nature Publishing Group 
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Figure 1.4: Left: MRCP (left) and ERCP (right) showing typical, multiple strictures and 
dilatations of the biliary tree (41). 
 
1.5.2 Pathogenesis 
The etiology and pathogenesis of PSC is incompletely understood, but probably involves 
both genetic susceptibility and environmental factors. There are different theories on whether 
the original injury to the bile ducts is caused by immune-related mechanisms or biochemical 
factors associated to bile toxicity (42).  
 
1.5.2.1 Autoantibodies  
The observation that PSC patients have many circulating autoantibodies has led to the 
hypothesis that PSC is caused by immune reactions against self-antigens (43). Further 
support for this is the strong risk factors correlated to certain HLA haplotypes (44), but also 
the fact that 25% of PSC patients are reported to have other, coexisting autoimmune diseases 
(45). However, the specificity of many of the detected autoantibodies is relatively low, and it 
is often argued that they arise due to secondary responses, following the sustained 
inflammation, rather than as a consequence of autoimmunity against a specific target 
autoantigen (43).  
Examples of such non-specific antibodies detected in PSC and in other autoimmune liver 
diseases are anti-nuclear (ANA), anti-cardiolipin, and anti-smooth muscle (SMA) antibodies 
(43), as well as antibodies against neutrophil components (ANCAs) (46). However, the 
identification of β-tubulin isotype 5 (TBB-5) as a candidate autoantigen for ANCAs, suggests 
that PSC patients might have a dysregulated immune response to intestinal microbes, since 
TBB-5 shares high structural homology with the bacterial cell division protein FtsZ (47).  
 
   13 
1.5.2.2 T cells  
Several experimental studies suggests T cells to be highly involved in the pathogenesis of 
PSC (42). The strong association with IBD indicate that the immune system may be triggered 
by bacterial compounds from the gut (48). Experimental data further support this. Bile from 
PSC patients have been shown to contain increased levels of bacterial species, with the 
capability to induce expansion of Th17 and Th1/Th17 cells in peripheral blood (49). 
Moreover, mechanistic studies suggest that the biliary injury is caused by cytotoxic CD8+ T 
cells, initially activated in the gut (50). Such observations led to the hypothesis of “aberrant 
homing of lymphocytes”, presented by Adams et al. 2006, which is further explained in the 
next section.  
 
1.5.2.3 Lymphocyte recruitment and homing 
The fact that PSC can occur in IBD patients after colectomy, and IBD arise in PSC patients 
after liver transplantation, has led to the hypothesis of aberrant lymphocyte homing. 
According to this theory, activated T cells in the gut are proposed to persist as memory cells 
and may be recruited to the liver by aberrant expression of mucosal addressin cellular 
adhesion molecule 1 (MADCAM-1) and CC chemokine ligand (CCL) 25 on the liver 
endothelium. The up-regulation of these molecules leads to the recruitment of gut-resident 
CCR9+ α4β7-integrin+ lymphocytes. Epithelial produced chemokines, such as CXCL12, 
CXCL16, and CX3CL1, place them around bile ducts, and upon encountering of antigen(s), 
they become activated and promote inflammation (51, 52).  
 
1.5.2.4 Exposure to endotoxins 
Bile fluids of PSC patients have been shown to be frequently colonized with bacteria (49). 
Alterations in the epithelial barrier, due to overexposure to microbial compounds, might be an 
explanation to the biliary injury. Studies in animal models have shown that the disruption of 
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epithelial tight junctions leads to a leakage of bile into the portal tracts, followed by an 
inflammatory response. This response includes influx of T cells, activation of myofibroblasts 
and development of fibrosis (51). Furthermore, BECs from PSC patients have been observed 
to express higher levels of TLRs, TNF-α, IFN-γ and IL-8, than in patients without PSC, 
suggesting an exaggerated innate immune response (52). 
 
1.5.2.5 Toxic bile 
There is evidence that toxic bile directly or indirectly might be involved in the pathogenesis 
of PSC. Cholestasis in itself can lead to damage of the liver cells, since it naturally leads to an 
accumulation of bile acids. This is a common characteristic of all cholestatic diseases (53). 
However, genetic findings suggest that the toxic effect of bile acids in PSC may be more 
specific and caused by defects in the secretion functions of biliary epithelial cells (54). 
Dysfunction in the multidrug resistance protein (MDR) 3 gene leads to bile-duct injury, as a 
consequence of an abnormal composition of bile acids. MDR3 encodes a transporter protein, 
whose function is to secrete phospholipids, that together with cholesterol encloses the bile 
acids in micelles, which protects the biliary epithelium from toxicity (53). Mice, that are 
devoid of this gene, have been observed to have PSC-like intrahepatic changes with disrupted 
tight junctions, leakage of bile acids into the portal tracts and infiltrating inflammatory cells 
(51). However, no direct association between PSC and defects in MDR3 have been found 
(55).  
Variations found in the gene encoding the bile-salt-sensing receptor TGR5 may be of more 
importance in PSC pathogenesis (54). It is involved in the complex regulation of HCO3- 
secretion and defects in this system has led to the hypothesis of a protective HCO3- umbrella 
(56). According to this theory, damage to the BECs is caused by reduced concentrations of 
secreted chloride and bicarbonate into the bile ducts. This makes BECs more vulnerable to 
bile acids, as the protective glycocalyx layer (termed glycocalyx umbrella) disappears. 
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Irrespective of whether toxic bile acids are the direct cause of inflammation in PSC or not, 
their leakage into the parenchyma likely contributes to the acceleration of disease, with 
worsened fibrosis as a result.  
 
1.6 GENETICS 
First-degree relatives of PSC patients have a 9- to 39-fold increased risk of developing the 
disease (57) and the strongest risk factors are located within the MHC complex, at 
chromosome 6p21 (58). Most of the genes identified as being risk associated in PSC are 
related to inflammation. Classic examples include the HLA class I and II genes (59), whose 
encoded proteins direct the T cell response. Other risk-associated genes that have been found 
include IL2/IL21, REL and CARD9 (60). This further suggests that inflammation plays an 
important role in PSC, since all of these genes encode proteins that are implicated in the 
activation and function of immune cells (61). Several PSC-associated susceptibility genes 
have also been found outside the MHC region, such as CD28 and CD226 (58). These genes 
encode receptors that are involved in co-stimulation of T and NK cells respectively (62), 
suggesting components of both the innate and adaptive immune system to be involved in the 
pathogenesis of PSC. Gene variants have also been identified in MST1, whose protein 
product is implicated in the suppression of macrophages (61). Taken together, even though 
no PSC-specific susceptibility loci have been identified so far, several genetic findings 
suggest that PSC might be caused by immune-mediated mechanisms.  
Despite several proposed hypotheses and the recent identification of new genetic 
susceptibility loci in PSC, the pathogenesis still remains incompletely understood. The main 
reason for this is that when PSC is diagnosed, the disease has often progressed to a late stage. 
By that time it is impossible to know whether the molecular changes observed are the direct 
causing factors, or secondary effects due to inflammation. However, heterogeneity within the 
PSC population suggests that several pathogenic mechanisms may be involved at different 
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stages of the disease. 
 
1.7 CHOLANGIOCARCINOMA 
CCA is the malignant transformation of the biliary epithelium. Although it is a rare form of 
cancer, it is the second most common primary liver cancer after hepatocellular carcinoma 
(HCC), and accounts for approximately 3% of all gastrointestinal tumors (63). The difficulty 
of early diagnosis is a contributing factor to the low survival of the patients. The median 5-
year survival is as low as 10% (64) and due to severity of fibrosis or a poor health, only a 
third of the patients can undergo curative liver resection (65). The anatomical location of the 
tumor along the biliary tree determines the classification of CCA (66). If it originates from 
small intrahepatic ductules or large intrahepatic ducts, close to the right and left hepatic ducts, 
it is classified as intrahepatic CCA. Extrahepatic CCA is the collection name for hilar 
cholangiocarcinomas (also called Klatskin tumors) and distal tumors. These two subtypes are 
anatomically separated from each other by the cystic duct. Perihilar CCA is the most 
common form of CCA and accounts for 50-67% of all cases (67). The surgical options for 
patients diagnosed with perihilar CCA are limited (68). The different subtypes of CCA differ 
in epidemiology, etiology, pathogenesis and treatment possibilities (63). 
The pathogenesis of CCA is insufficiently known, and, there are no early, reliable detection 
markers. Early diagnosis is difficult, especially in PSC where the biliary tree has strictures. 
CA19-9 is the most commonly used serum biomarker for CCA. This marker is unfortunately 
unspecific and can also be increased in bacterial cholangitis, cholestasis and other 
malignancies (69).  
Chronic inflammation is an established risk factor for CCA and PSC patients have 160 times 
higher risk than the general population of developing CCA (70). PSC patients develop CCA 
much earlier than the patients without PSC. The age of onset among individuals with PSC is 
about 40 years (74), while it is over 70 years for the non-CCA patients (75). Furthermore, a 
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PSC patient often receives the diagnosis of CCA within one year from the determination of 
PSC (71). Thus, the duration time of PSC does not seem to be linked to the malignant 
transformation, even though inflammatory factors are assumed to be probable causes for the 
progression to cancer. Evidence for this is the association of CCA with other inflammatory 
diseases in the liver, such as parasitic infections and hepatitis B and C infections (72).  
A commonly observed phenomenon in various cancers is the infiltration of suppressive 
immune cell subsets, such as regulatory T cells (Tregs) (73). This infiltration is often 
beneficial for the tumor cells, since the functions of Tregs commonly lead to a decreased 
capacity of cytotoxic immune cells to kill tumor cells. Studies in CCA have led to different 
observations. Positive associations have been made between infiltrating Tregs and the pro-
inflammatory subset of T cells, known as IL17+ cells (74). This was further correlated with a 
poorer survival for the patients. In another study of CCA, infiltrating Tregs were reported to 
associate with increased numbers of alternatively activated macrophages (M2 cells) (75). 
These cells are known to have anti-inflammatory properties (76). Moreover, no unifying 
results have been obtained from studies of cytotoxic T lymphocytes (CTLs) and their 
functions in CCA. Some studies found CCA tumors to contain lower numbers of CTLs than 
the surrounding tissue (74), whereas another study observed similar CTL levels inside as 
outside the tumor (77). 
In addition to risk factors such as inflammation, the genetic profile of the patients probably 
also has a significant role. Variations in the gene encoding the activating natural killer 
receptor G2D (NKG2D) have been associated with risk for CCA in PSC patients (78). 
NKG2D has an important role in tumor surveillance (79) and variants in the gene encoding 
its ligand, MICA, have also been identified in CCA, as well as in HCC. This suggests that the 
MICA-NKG2D axis might have an overall role in the development of hepatobiliary cancer 
(80). 
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In conclusion, inflammation is strongly linked to CCA and other cancer forms. Some cancers 
are preceded by an inflammatory condition, whereas in others, inflammation develops due to 
the malignant transformations (81). Regardless of what comes first, the tumor cells are often 
favored by the immune suppressive nature of the cancer-related inflammation (73). A better 
understanding of the inflammatory cells involved in the cancer-related inflammation can lead 
to the development of targeted therapies against these cellular factors. 
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2 AIMS  
The general aim of this thesis was to improve the understanding about pathogenic 
mechanisms in PSC and the PSC-associated malignancy CCA, by exploring both humoral 
and cellular aspects of the immune response.  
 
Aim of study I: 
To evaluate the presence of autoreactive IgA antibodies in PSC patients. 
 
Aim of study II: 
To characterize non-parenchymal intrahepatic cells in PSC livers and to investigate 
associations between immune phenotypes and PSC disease severity. 
 
Aim of study III: 
To enumerate innate and adaptive immune cell subsets in CCA in livers from PSC and non-
PSC patients.  
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3 MATERIAL AND METHODS 
 
3.1 ETHICAL CONSIDERATIONS  
Informed written consent was obtained from all patients and the Regional Ethics Committee, 
Stockholm, Sweden, approved the studies. 
Material from deceased liver donors were included in the studies according to the regulations 
of the organ transplantation law of Sweden (1995:831), that is, the donors prior written 
declaration was followed as well as the written informed consent from next of kin. 
 
3.2 PAPER I 
 
3.2.1 Clinical material 
Serum samples from 81 PSC patients were used in this study. The samples had been collected 
while the patients underwent routine controls, at our Unit at Karolinska University Hospital 
in Huddinge, during a total time period of 16 years. The diagnoses of PSC and IBD were 
based on biochemical, clinical, and cholangiographic features, typical history, and 
characteristic endoscopic and histologic findings (41). Serum was collected from 42 healthy 
volunteers, and all samples were cryopreserved until later usage. For isolation of liver cells, 
tissue from donor livers, not used for transplantation because of technical reasons, were 
collected.  
 
3.2.2 Establishing cultures of BECs  
To avoid the risk that a possible autoantigen had been destroyed by earlier immune attack 
following inflammation, we chose to isolate human BECs from livers of deceased individuals 
with no known liver diseases. The tissue was disintegrated into small pieces, thereafter 
enzymatically digested with 0.05% Collagenase V and 0.002% DNAse to release the cells. 
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The liver digest was filtered and washed, thereafter the mixed cell population was 
resuspended in epithelial cell medium (ECM) and grown until confluence in gelatin-coated 
tissue culture flasks. Selection for epithelial cells was performed using immunomagnetic 
isolation with EpCAM-conjugated (clone HEA-125) microbeads. Enriched cells were further 
cultured and used freshly before reaching passage 6, or cryopreserved in liquid nitrogen for 
later usage. The EpCAM-selected cells were observed for the characteristic cuboidal 
morphology of epithelial cells with a phase contrast microscope. 
 
3.2.3 Phenotypic characterization of isolated cells by flow cytometry 
EpCAM-enriched cells were characterized by flow cytometry for epithelial markers such as 
EpCAM, Cytokeratin 19 (CK19) and Cytokeratin 7 (CK7), and for non-epithelial markers 
such as CD90, CD31, CD45, α-SMA, Calponin and Caldesmon. Antibody staining was 
performed with monoclonal antibodies, either on primary liver cells or isolated, passaged 
cells. Levels of background staining were assessed with corresponding isotype control. 
Samples were acquired using a FACS Calibur flow cytometer and analyzed using FlowJo 
version 9.3. 
 
3.2.4 Detection of autoreactive IgA and IgG antibodies in patient sera 
EpCAM-enriched cells were stimulated overnight with 20 ng/ml TNF-α and 200 ng/ml IFN-
γ, according to a previously described method (82). Before staining, the single-cell 
suspension was incubated with patient or control sera, diluted 1:4 in PBS, at room 
temperature for one hour. Unbound antibodies were washed away and thereafter the cells 
were incubated with secondary fluorescein isothiocyanate (FITC)- conjugated goat anti- 
human IgA antibody or cyanine (CY) 3- conjugated rabbit-anti IgG. Samples were acquired 
using a FACS Calibur flow cytometer and analyzed using FlowJo version 9.3. 
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3.2.5 Data Analysis 
Statistical analyses were carried out using Graphad Prism software version 5.0. The 
parametric two-tailed Student´s t-test was used, since the groups were large enough 
(containing more than 15 observations) and normally distributed. Linear regressions were 
performed to investigate the degree of correlation between two variables. Deviations between 
the variables were visualized using r 2 values. Kaplan Meier survival analyses were 
performed, with comparison of survival curves using the Gehan–Breslow–Wilcoxon test. 
Hazard ratios were calculated using the Mantel–Haenszel method, for assessment of the rate 
of deaths in the two groups (a hazard ratio of 2.0 means that the rate of deaths is twice the 
rate in the other group) (www.graphpad.com). Follow-up time was calculated from PSC 
diagnosis to the date of liver transplantation or death. 
 
3.3 PAPER II 
 
3.3.1 Patients and liver tissue  
Liver tissue from 17 patients with PSC and 17 non-PSC controls were used in this study. 
Sixteen of the PSC patient samples were received at the time of liver transplantation, and one 
was obtained from a patient undergoing liver resection due to suspicion of CCA. As control 
samples, tissues from four donor livers (not used for liver transplantation because of technical 
reasons) and 13 patients undergoing liver resection due to suspicion of cancer, were included. 
All the obtained samples were from non-tumor-affected areas of the resected livers, as far 
away from the resection margin as possible. Patients with cholestatic disease or primary liver 
cancer were excluded from the non-PSC cohort. Upon collection, all liver specimens were 
embedded in Tissue-Tek OCT, snap-frozen, and stored at −80°C until sectioning. 
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3.3.2 Gene expression analysis  
For the measurement of gene expression, total messenger (mRNA) was extracted from liver 
tissues with Trizol, based on the protocol by the manufacturer. Complementary (c)DNA was 
produced by the use of Applied Biosystem´s High capacity cDNA reverse transcription kit. 
The DNA was amplified and quantified using TaqMan real time polymerase chain reaction 
(PCR), employing the Applied Biosystems 7500 Fast Real-Time PCR System. Expression 
levels of CK19, Caldesmon, NKp46, and HLA-A and HLA-B were calculated from the cycle 
threshold (Ct) values against the endogenous housekeeping gene Cyclophilin A, using the 
comparative delta-Ct method.   
 
The remaining methods; histological grading, immunohistochemistry, automated image 
analyses and statistical analyses, are the same as for paper III and therefore described 
further below. 
 
3.4 PAPER III 
 
3.4.1 Patients and liver tissue  
Twenty CCA-patients and five non-CCA controls were enrolled in this study. Liver tissue 
specimens were obtained from patients admitted for liver resection at Karolinska University 
Hospital, for reason of a primary malignancy in the liver. Inclusion criteria were a diagnosis 
of CCA, which was confirmed by routine pathology. Control samples were obtained from 
five patients undergoing liver resection due to suspicion of gall bladder cancer, but where no 
cancer was found in the surgical specimen and the liver histology was evaluated to be normal. 
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3.5 PAPER II & III 
 
3.5.1 Histological grading  
Liver tissues were sectioned into a thickness of 5 µm and placed onto SuperFrost Ultra Plus 
slides. To visualize the histology, the samples were stained with hematoxylin and eosin. 
Thereafter a liver pathologist, who had no information about the included patients, evaluated 
the samples with regard to inflammation (grade) and fibrosis (stage), based on a non-
continous, 0–4 graded scale. Levels of bile duct proliferation were assessed using a scoring 
method with; 0 = 1–2 bile ducts per portal zone, 1 = 3–4 ducts per portal zone, evaluated as 
minimal proliferation, 2 = 5–7 ducts per portal zone, corresponding to a moderate 
proliferation, 3 = 8 or more bile ducts per portal zone, corresponding to intensive 
proliferation (83).  
 
3.5.2 Immunohistochemistry  
Immunostainings were performed using the ImmPRESS system (Figure 3). Briefly, sections 
were air-dried for 10 minutes and thereafter fixed in 4% paraformaldehyde for 20 minutes on 
ice. For intracellular staining, fixation and permeabilization was performed with 
Foxp3/Transcription Factor Staining Buffer Set (study III). Sections were incubated with 
Bloxall (10 minutes), followed by Innovex background Buster (20 minutes) to reduce 
unspecific background stainings. Samples were incubated with primary antibodies over night 
at +4˚C. Secondary ImmPRESS antibodies were added to the sections for 30 minutes at room 
temperature, and specific staining was detected by incubation with ImmPACT DAB. Finally, 
tissue sections were counterstained with Hematoxylin and mounted with Kaisers´s glycerol 
gelatine.   
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Figure 3. Brief description of the general concept behind immunohistochemistry, and the 
ImmPRESS method used. In a first step, primary antibody, targeted against the specific 
protein of interest, is added. In step two, the bound primary antibodies are captured with a 
peroxidase-conjugated secondary antibody. In the last step, the enzyme substrate for 
peroxidase, 3,3´-diaminobenzidine (DAB), is added. This will lead to the development of a 
brown reaction product, which makes the detection of the protein possible and further 
measurable for image analysis. 
 
3.5.3 Automated image analysis 
IHC-stained specimens were analyzed by acquired computerized image analysis (ACIA) in a 
blinded fashion, that is, without knowledge of which samples that were controls and which 
ones that were patients. Fifteen to twenty consecutive photomicrographs were taken from 
each tissue section, which covered the majority of the sample area. ACIA-values were 
calculated as the percentage of area stained positively by a phenotypic marker, multiplied by 
the mean intensity of the positive staining. 
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3.5.4 Data Analysis 
Statistical analyzes were performed using Prism version 6.0 (84). Kolmogorov-Smirnov or A 
D´Agostino-Pearson omnibus test were performed to probe if values were normally 
distributed. The Students t test was used when the investigated population assumed a normal 
distribution. If not, the nonparametric statistical test, Mann Whitney U test, was used. For 
comparison of paired samples, a paired t test was used, when the values had a Gaussian 
distribution. Otherwise, the Wilcoxon matched pairs test was performed. One-way ANOVA 
(parametric) or Kruskal Wallis (nonparametric) tests were applied for multiple groups. To 
analyze the pairwise differences between any of two groups, a Bonferroni or a Dunn´s post-
analysis was performed, after a parametric and nonparametric test, respectively. For 
correlation analyzes, linear regressions were performed. Principal component analysis (PCA) 
was performed using Qlucore OmicsExplorer v2.2, to identify the largest variances between 
included variables
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4 RESULTS 
 
4.1 PAPER I 
 
4.1.1 Patients 
The clinical characteristics of the patients and controls included in this study are presented in 
Table 1. The median age of the PSC patients was 58 years (range 25-94). The distribution 
between males and females was 63% and 37% respectively. The median age of the controls 
was 48 years (range 28-71), with 24 males (57%) and 18 females (43%). Eighty percent of 
the PSC patients suffered from IBD, and 53% of the total numbers of patients reached clinical 
endpoint during the follow-up period. 
 
Table 1. 
Clinical characteristics of patients and controls in paper I. 
 Controls (n=42) PSC patients (n=81) 
Age, median (range) 48 years (28-71) 58 years (25-94) 
Male 24 (57%) 51 (63%) 
CCA NA 10 (12%)1 
IBD NA 65 (80%) 
Colectomy NA 15 (19%)2 
Duration of PSC disease  NA 89 months (4 – 408) 
Ltx or death NA 43 (53%) 
Follow-up time  NA 65 months (1 – 164) 
Abbreviations: CCA = cholangiocarcinoma; IBD = inflammatory bowel disease; UC =  ulcerative 
colitis; CD = Crohn’s disease; Ltx = liver transplantation. 
1Information not available in four patients; 2Information not available in five patients. 
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4.1.2 Establishment of biliary epithelial cell-selected cultures 
After mechanic and enzymatic digestion of healthy human liver tissues, a population of cells 
that expressed the biliary epithelial-specific markers epithelial cell adhesion molecule 
(EpCAM), cytokeratin (CK) 7 and CK19 was identified with flow cytometry (Figure 4.1).  
 
 
Figure 4.1: Characterization of primary and in vitro expanded biliary epithelial cells. 
Representative stainings for EpCAM and CD31 on freshly isolated liver cells and for CK19 
and CK7 after gating for EpCAM-positive (solid black line), CD31-positive (dashed black 
line), and EpCAM-negative CD31-negative (solid gray histogram) cells. 
 
After four to six passages, the cells started to express molecules often associated with fibrotic 
processes, such as α-SMA, calponin, caldesmon, and CD90 and had lost their expression of 
EpCAM and BerEp (another antibody clone for epithelial adhesion molecule). However, as a 
control for purity of the cultures, cells also stained negative for the endothelial marker CD31 
(Figure 4.2).  
 
 
Figure 4.2: Representative stainings for EpCAM, BerEP, and CD31 (all solid black lines) on 
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biliary epithelial-enriched cells after six passages. Solid gray histograms represent isotype 
controls. 
 
4.1.3 PSC patients have autoreactive IgA and IgG antibodies 
Serum from a total of 81 PSC patients and 42 healthy controls was investigated for the 
presence of serum IgA and IgG with reactivity against the EpCAM-selected cells. Using MFI 
measurements, with a MFI cut-off set to the highest MFI value of the healthy control group, 
65% of the investigated PSC patients were shown to have IgA that reacted against the cells 
and 68% had reactive IgG antibodies (Figure 4.3). Only low or no binding could be detected 
when applying serum from healthy controls (Figure 4.4).  
 
  
 
Figure 4.3: Geometric MFI for IgA (left) and IgG (right) binding to epithelial-enriched liver 
cells summarized for the patients and controls.  
 
 
Figure 4.4: Representative flow cytometry staining for IgA (black solid line) and isotype 
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control (gray solid histogram) on epithelial-enriched liver cells using serum from one healthy 
control and three PSC patients. The figure shows that PSC patients have antibodies that react 
against biliary epithelial-enriched cells. 
 
4.1.4 Levels of autoreactive IgA is associated with higher total levels of 
circulating IgA antibodies 
Since a majority of the patients were found to have reactive antibodies against the selected 
cells, we next investigated possible underlying factors that could explain their appearance in 
the sera. For this purpose, levels of autoreactive IgA and IgG were correlated with total serum 
concentrations of IgA and IgG in the patients. We found that patients who were autoreactive 
IgA-positive had higher levels of total serum IgA than the patients that were autoreactive 
IgA-negative. No such correlation was found between serum IgG and autoreactive IgG levels.  
Another possible explanation for the presence of autoreactive antibodies in PSC patient sera 
could be secondary effects, following long disease duration with chronic inflammatory and 
fibrotic processes in the liver. However, when levels of autoreactive IgA and IgG antibodies 
in PSC patient sera were correlated with the median duration of PSC disease, no such 
association was found.   
 
4.1.5 Autoreactive IgA is associated with more rapid PSC disease 
progression 
Next, we wanted to investigate if the presence of autoreactive antibodies in PSC patient sera 
could be connected to disease characteristics. When investigating this, we found that the 
levels of autoreactive IgA or IgG in the patients were neither correlated with age, gender or 
later development of CCA. No correlation was either found between the presence of 
autoantibodies and a coexisting IBD in the patients.  
Finally, we wanted to investigate if disease progression was affected by the presence of 
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circulating autoantibodies in PSC patient sera. Survival analysis studies were performed to 
evaluate this, using death or liver transplantation as the clinical endpoints. Autoreactive IgA-
positive PSC patients were found to progress more rapidly to a clinical endpoint than 
autoreactive IgA-negative patients, with a hazard ratio of 1.78 (p = 0.03) (Figure 4.5). A 
similar association could not be found for autoreactive IgG-positive patients.  
 
 
Figure 4.5: Autoreactive IgA is associated with more rapid PSC disease progression. Kaplan 
Meier survival analysis comparing the effects of having IgA autoantibodies on progression of 
disease defined as liver-transplantation-free survival. PSC patients were subdivided into 
autoantibody-positive and -negative patients. As a cut-off for IgA in the patients, the highest 
measured geometric MFI of the healthy controls was used.  
 
4.2 PAPER II 
 
4.2.1 Patients  
The clinical characteristics of patients and their evaluated liver histology are presented in 
Table 2. Ten of the patients (59%) were male and 7 (41%) were female. Four patients were 
histologically assessed as having a mild disease and 13 patients as having a severe disease. 
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Table 2.  
Clinical characteristics of patients and controls in paper II. 
 Controls (n = 17) PSC patients (n = 17) 
Age, median (range) 58 (16-86) 36 (19-68) 
Male 9 (53%) 10 (59%) 
IBD 01 14 (82%) 
Ltx 0 16 (94%) 
MELD score, mean ± SD NA 13 ± 8 
Serum IgG (g/L), mean ± SD NA 15.5 ± 4.6 
ALP (µkat/L), mean ± SD 1.8 ± 1.0 5.4 ± 4.4 
Bilirubin (µmol/L), mean ± SD 7.9 ± 4.9 89.2 ± 166.1 
ALT (µkat/L), mean ± SD  0.6 ± 0.2 1.3 ± 0.7 
CRP (mg/L), mean ± SD  5.3 ± 6.6 24.4 ± 32.9 
UDCA dose (g/day), mean ± SD NA 0.8 ± 0.6 
Fibrosis stage 
0/1/2/3/4 
12/5/0/0/0 0/4/0/0/13 
Inflammation grade, 0/1/2/3/4 14/3/0/0/0 4/4/9/0/0 
Bile duct proliferation stage, 
0/1/2/3 
3/14/0/0 3/2/7/5 
Abbreviations: IBD = inflammatory bowel disease; UC = ulcerative colitis; CD = Crohn´s disease; NA = not 
applicable, Ltx = liver transplantation, MELD = Model for End-Stage Liver Disease, SD = standard deviation, 
ALP = alkaline phosphatase, ALT = alanine aminotransferase, CRP = C-reactive protein, UDCA = 
ursodeoxycholic acid 
1Information not available for four controls 
 
4.2.2 IHC characterization of non-parenchymal non-immune cells in PSC-
patient livers 
After IHC staining for several different cellular subsets of non-immune origin, we could 
conclude that our results support previous findings regarding increased numbers of BECs in 
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PSC patients. All the BEC-specific markers (CK7, CK19 and EpCAM), were significantly 
increased (visualized for CK19 in Figure 4.6), whereas numbers of endothelial cells were at 
the same levels in patients and controls.  
 
Figure 4.6: Representative immunostaining and quantification analysis of CK19 expression 
in controls and PSC patients. Samples were counterstained with hematoxylin and DAB 
chromogen provided the brown reaction product, identifying the biliary epithelial cells. 
Quantification of protein expression was performed by calculating both the intensity of the 
IHC staining (ACIA) and the frequency of cells that expressed the protein (percentage of 
stained area of the total area).  
 
4.2.3 Gene expression analysis 
When investigating the gene expression of CK19, only a trend toward elevated levels of 
CK19 mRNA was detected in the patients compared to the controls. No significant difference 
could either be observed for NKp46, HLA-A and HLA-B mRNA, although the total protein 
expression of HLA class I was significantly reduced in patients compared to controls, as 
revealed by the IHC stainings.  
 
4.2.4 T cells infiltrate PSC-patient livers and localize to fibrotic fields 
Next, we wanted to locate and enumerate different immune cell populations in patients and 
control livers. IHC staining and image analysis was performed to quantify the expression of 
CD3, TCR-Vα7.2, NKp46 and CD163. Protein levels of MHC class I were examined (HLA-
A, B, C) as well. Our data reveal that the total numbers of CD3+ T cells in PSC patients were 
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significantly higher than in controls, and that these cells specifically localized to fibrotic areas 
(Figure 4.7). MAIT cells exhibited a similar pattern, but were not more numerous in the 
patients than in the controls (Fig 4.7). CD163 was more strongly stained in the patients, 
whereas no difference was seen for NKp46 expression. Both Kupffer cells and NK cells were 
evenly distributed throughout the parenchyma with no specific accumulation in fibrotic areas. 
 
 
Figure 4.7: Representative immunostaining and quantitative determination of intensity of 
staining (ACIA) of CD3 and TCR-Vα7.2 in fibrotic and non-fibrotic areas in PSC patient 
livers.  
 
4.2.5 Low expression of Caldesmon in PSC-patients correlates with higher 
numbers of T cells and more extensive bile duct proliferation 
Immunohistochemistry and enumeration for Caldesmon expression was performed, since 
smooth muscle cells might participate in processes leading to development of fibrosis. No 
significant differences in protein expression could be detected between patients and controls, 
however, some patients were distinguished by being almost completely negative for 
Caldesmon expression (Caldesmonneg), while the other patients had a similar expression level 
as the controls (Caldesmonpos) (Figure 4.8). The two groups were compared regarding 
expression of phenotypic markers and histological parameters. Caldesmonneg patients had 
significantly higher expression of CD3 and a more extensive bile duct proliferation than 
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Caldesmonpos patients (Figure 4.9).  
 
 
Figure 4.8: IHC and quantitative image analysis of Caldesmon, showing one control (left), 
one PSC patient with a negative expression (right) (Caldesmonneg), and one PSC patient with 
similar level of expression as the control (middle) (Caldesmonpos).  
 
 
Figure 4.9: Quantification with image analysis of CD3 expression in controls and PSC 
patients with positive (pos) or negative (neg) expression of Caldesmon (left). Linear 
regression analysis of Caldesmon expression versus bile duct proliferation in the PSC-
patients (right). 
 
4.2.6 Principal component analysis of non-parenchymal liver cells in PSC 
Having analyzed a total of 23 unique parameters, including both phenotypic markers and 
histological scores, we next wanted to identify factors that distinguished patients from 
controls, and further, within the PSC group, identify patterns associated with disease severity. 
PCA was first performed to compare the expression pattern in patients and controls. 
Histological scores (fibrosis, inflammation, and bile duct proliferation) were in this first set of 
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analysis excluded (Figure 4.10). Thereafter, a second analysis was performed, with inclusion 
of histological scores, to identify phenotypic markers that differentiated patients with respect 
to severity of fibrosis or bile duct proliferation (Figure 4.10). The results revealed that 
numbers of bile duct cells, T cells, Kupffer cells, and MHC class I expression, were all 
phenotypic factors that significantly distinguished PSC-patients from controls. In the next 
analysis,  
EpCAM and NKp46 were identified as phenotypic factors that distinguished patients with 
mild from severe fibrosis, whereas Caldesmon and CK19 separated patients according to 
stage of bile duct proliferation (Figure 4.10). 
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Figure 4.10: PCA plot showing phenotypic factors that separate PSC patients from controls 
(upper). In the next PCA, PSC patients were compared according to severity of disease, with 
inclusion of scores of fibrosis (middle) and bile duct proliferation (lower).   
 
4.3 PAPER III 
 
4.3.1 Patients 
The clinical characteristics and histological scores of the patients included in this study are 
presented in Table 3. In total, 20 CCA patients (11 males and 9 females) and 5 non-tumor 
controls (2 males and 3 females) were included in the study. The median age was 63 years 
(range 30-81) for the CCA-patients and 67 years (range 53-70) for the controls. 
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Table 3. 
Clinical characteristics of patients and controls in paper III. 
 Controls 
(n=5) 
CCA patients 
(n=20) 
Age, median (range) 67 (53-70) 63 (30-81) 
Male 2/5 11/20 
PSC NA 5/20 
Intrahepatic tumor NA 14/20 
Tumor differentiation (low/moderate) NA 13/61 
ALP (µkat/L), mean ± SD 1.3 ± 0.5 4.4 ± 2.6 
Bilirubin (µmol/L), mean ± SD 12.4 ± 15.6 16.2 ± 36 
CRP2 (mg/L), mean ± SD 12.4 ± 22.2 38.5 ± 44.2 
Fibrosis score3 
0/1/2/3/4 
2/3/0/0/0 6/12/2/0/0 
Inflammation grade3 
0/1/2/3/4 
4/1/0/0/0 10/9/0/1/0 
Bile duct proliferation stage3  
0/1/2/3 
1/3/1/0 2/8/7/3 
 
Abbreviations: ALP = alkaline phosphatase; CRP = C-reactive protein;  
PSC = primary sclerosing cholangitis; SD = standard deviation.  
1Information not available from one patient; 2CRP was measured the day before surgery;  
3Non-tumorous tissue 
 
4.3.2 IHC characterization and quantitative image analysis of non-
parenchymal non-immune cells of CCA-patient livers 
We characterized non-parenchymal intrahepatic cells of immune as well as of non-immune 
cell origin in CCA-patients and controls. Expression of CK19, CD31 and Caldesmon were 
assessed with IHC and quantitative determination. As expected, CK19 was more dramatically 
increased in the tumorous areas of the CCA patients than in the non-tumorous areas, and also 
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in comparison to the non-CCA controls, whereas no change in presence of endothelial cells 
or smooth muscle cells were detected in the tumor areas. 
 
4.3.3 MAIT cells and Kupffer cells are selectively lost in the CCA 
microenvironment 
The establishment and growth of tumors are tightly linked to the numbers and composition 
different immune cell subsets in the tumor microenvironment (85).  
Immunostainings were performed to enumerate CD3+ T cells, CD8+ cytotoxic T 
lymphocytes, TCR-Vα7.2+ MAIT cells and CD163+ Kupffer cells in controls and in non-
tumorous and tumorous areas of CCA-patients. Few, if any, differences were present when 
comparing the non-tumorous areas of CCA-patients with the control tissues. Furthermore, the 
tumor areas contained similar levels of CD3+ and CD8+ cells as in the surrounding non-
affected areas. Instead, a selective two-fold loss of TCR-Vα7.2 and CD163 expression was 
noted in the tumorous areas (Fig. 4.11). In summary, these results indicate that the 
intratumoral compartment in CCA has preserved numbers of T cells and CTLs but a selective 
loss of innate MAIT cells and Kupffer cells. 
 
 
Figure 4.11: Representative immunostainings (left) of TCR-Vα7.2 (upper) and CD163 
(lower) expression in controls, non-affected and affected areas of CCA patient livers. 
Samples were counterstained with hematoxylin and dark brown indicate immunoreaction 
  40 
product. Quantitative analysis (right) of the mean intensity of TCR Vα7.2 and CD163 IHC 
stainings (ACIA) in controls, and non-affected and affected areas in CCA patient livers. 
 
4.3.4 Retained Th1 but diminished Th2 responses in the tumor 
microenvironment 
Having observed that the tumor areas of CCA-patients contained less innate immune cells 
than the surrounding non-tumorous areas, we next wanted to investigate the shape of the 
adaptive immune response within the tumor. Expression levels of perforin, IL-33, and Foxp3 
were measured, reflecting Th1, Th2, and regulatory immune responses respectively. In 
summary, CCA tumors were characterized as having conserved Th1, but clearly reduced Th2 
responses, and high numbers of regulatory T cells. This was evident by the sustained 
expression of perforin, significantly lower protein levels of IL-33 and higher levels of Foxp3 
(Figure 4.12). 
 
 
Figure 4.12: Quantification of the mean intensity of staining (ACIA) of Foxp3, IL-33, 
Perforin and Caspase-3, in non-affected and affected areas of CCA patients and in non-
affected and affected areas of CCA-PSC patients.  
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4.3.5 Underlying PSC, tumor location, and degree of tumor differentiation 
are not associated with the revealed immune cell composition  
PSC is known to be one of the strongest risk factors for CCA, but there is limited knowledge 
about immunological differences between CCA livers with and without PSC. Thus, we 
evaluated the immune cell composition in the five PSC-CCA patient livers included in the 
study and compared it to the non-PSC CCA-patient livers. We also investigated if tumor 
location or the degree of tumor differentiation had an impact on the presence and numbers of 
cells. All the eleven included IHC-parameters previously studied were compared between the 
groups. We found that neither PSC nor tumor location nor tumor differentiation seemed to 
affect the immune cell pattern in CCA. 
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5 GENERAL DISCUSSION 
 
The general goal of this thesis was to improve the knowledge about pathogenic mechanisms 
in PSC. So far, no unifying explanation exists for how the chronic injury of the bile ducts is 
initiated in PSC. However, genetics as well as the observations of inflammatory infiltrates 
around portal tracts, other coexisting autoimmune diseases and many different autoantibodies 
in patient sera, suggests that specific immune reactions are of importance. With this 
knowledge as a basis, we aimed for investigating the presence and effect of autoantibodies in 
PSC patient sera, specifically targeted against biliary epithelial cells. Other aims were to 
study the intrahepatic localization and composition of various immune cell subsets in PSC 
patient livers, and in a subgroup of patients, diagnosed with cholangiocarcinoma.   
 
In paper I, we investigated the presence and effect of specifically targeted autoantibodies 
against BECs in PSC. We examined serum samples from 81 PSC patients and 42 controls, for 
IgG and IgA antibodies. The reactivity against isolated and cultured human BECs was 
explored and we found that most PSC patients had IgA antibodies that were reactive against 
the isolated cells, while few of the control samples showed any reactivity at all.  
 
The identification of autoantibodies, targeting a specific antigen in PSC, would be valuable 
from both diagnostic and prognostic purposes. However, studies to date suggest that 
autoantibodies in PSC arise as a result of secondary effects due to inflammation, rather than 
by a specific immune response towards the biliary epithelium. An early study (86) reported 
that sera from PSC and UC patients have autoantibodies that react with human tropomyosin 
isoform 5 (hTM5), a protein expressed in both intestinal and biliary epithelial cells. However, 
the specificity of this autoantibody is insufficient, since this protein is also found in the eyes, 
skin and cartilage, and furthermore, the presence of anti-hTM5 autoantibodies have been 
reported in sera from UC patients without PSC.  
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Why would autoreactive IgA antibodies form in PSC patients? We observed that PSC 
patients who were seropositive for autoreactive IgA generally had higher levels of total serum 
IgA. This observation led us to two different theories. One was that the inflammation itself 
causes an increased production of IgA antibodies, and that some of these antibodies react 
with endogenous proteins, exposed as a result of cell death. Another possibility is that the 
autoantibodies themselves contribute to the inflammatory process, and thereby accelerate the 
disease, with an increased total IgA production as a consequence. To investigate this, we 
correlated the presence of autoantibodies with disease duration. Since no association was 
found, we speculate that the appearance of autoantibodies might be related to factors other 
than prolonged inflammation.  
 
We found that PSC patients that were positive for autoreactive IgA antibodies at follow-up, 
reached clinical endpoint (death or liver transplantation) faster than patients that were 
negative for autoreactive IgA. The reason for this is unclear. The knowledge about the 
function of IgA antibodies in liver diseases is scarce although several studies suggest that 
elevated serum IgA levels are associated with reduced liver function and fibrosis (87). We did 
not have access to assessments of liver histology for the included patients, but since 
approximately half of them reached clinical endpoint within the follow-up period, it seems 
reasonable to believe that many of them were cirrhotic.  
 
The possibility that autoreactive IgA antibodies are produced in response to intestinal 
inflammation could not be excluded. However, no correlation could be found between the 
presence of IBD and autoreactive IgA antibodies in our patient cohort, suggesting that IBD, 
as a single parameter, has no effect on the formation of autoantibodies against the biliary 
epithelium. The specificity of these antibodies for PSC can also be questioned. Other 
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autoimmune or inflammatory liver diseases such as primary biliary cirrhosis (PBC) and 
autoimmune hepatitis (AIH) may also produce autoreactive IgA antibodies. Unfortunately, 
this question must be left open for further investigation, since we did not have access to such 
patient samples in this study.  
 
Sera from PSC patients and controls were reacted against EpCAM-selected, in vitro cultured 
liver cells in this study. After a few passages, the cells lost their expression of epithelial 
markers and started to express myofibroblast-like surface proteins, possibly indicating an 
epithelial to mesenchymal transition (EMT). Interestingly, previous studies have shown that 
the development of fibrosis in PSC patient livers is accompanied by an upregulation of EMT-
associated markers on the biliary epithelium (88), which possibly suggests that the cultured 
cells might have reflected a PSC-like in vivo situation. Although the precise cellular 
phenotype could not be identified, a majority of the patients had IgA antibodies targeted 
against the selected cells, which was further associated with a lower survival rate for the 
patients. The exact phenotype of the selected cells and the antigen(s) to which the antibodies 
bind, need further investigations.    
 
In summary, we found that the presence of IgA antibodies, targeted against biliary enriched 
cells, were associated with a lower survival for the PSC patients. Regardless of whether these 
autoantibodies are contributing factors to the inflammation in PSC, or if they arise as 
secondary effects due to it, their presence is evidence of an dysregulated immune response.   
 
A characterization and quantification of non-parenchymal cells in PSC livers has previously 
not been systematically and comprehensively performed. Such knowledge is of importance 
for better understanding of the inflammatory process in the liver and why it occurs. The 
biliary epithelium appear to be the main target for the immune attack in PSC, but less is 
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known about other non-parenchymal cells and how they are affected during the course of 
PSC disease (89). Many experimental studies have focused on investigating the role of T 
cells in PSC pathogenesis (42), and the proposed theory that PSC is driven by long-lived 
memory T lymphocytes, initially activated in the gut, represents an attractive link between 
PSC and IBD (90). The enterohepatic circulation of lymphocytes constitutes a possible 
explanation of how inflammation of the liver can occur long after an IBD patient has 
undergone colectomy. The purpose of the study in paper II was to characterize and quantify 
non-parenchymal cells in PSC livers and explore if specific phenotypic patterns were 
associated with severity of disease. In addition to the immunohistochemical characterization, 
followed by computer-based quantifications, a PCA was performed, to identify the 
phenotypic factors that most strongly separated PSC patients from healthy controls.  
 
Major findings were, as observed by the immunostainings, that CD3+ T cells were 
significantly more abundant in PSC patient livers than in controls and almost exclusively 
localized to areas of fibrosis. TCR Vα7.2+ MAIT cells, a recently discovered T cell 
population with an innate-like phenotype and the capacity to respond to bacterial stimulation 
(91), were not increased in numbers to the same extent. However, as the rest of the CD3+ T 
cell population, MAIT cells were preferentially localized to fields of fibrosis. Previous studies 
have shown that PSC patients have higher amounts of bacterial and fungal species in bile 
than controls and PBC patients have. Moreover, isolated bacterial compounds from PSC bile 
fluid were shown to initiate an increased number of Th17 and Th1/Th17 cells in peripheral 
blood (49). Since MAIT cells are competent producers of IL-17 (92), a cytokine that is 
described to be involved in fibrosis and pro-inflammatory interactions in the liver, it is 
tempting to speculate on the possibility that the expanding Th17 cells in the peripheral blood 
actually were MAIT cells. Although we did not see higher amounts of MAIT cells in PSC 
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patient livers than in controls, future investigations of the functions of MAIT cells in PSC 
will be of importance to determine a possible involvement in PSC disease.  
 
Experimental and genetic studies have shown that macrophages may be involved in the 
pathogenesis of PSC. Significantly higher numbers of Kupffer cells have been observed in 
PSC patients than in patients with primary biliary cirrhosis (PBC) and normal controls (93). 
The group behind this study proposed that Kupffer cells might be involved in early stages of 
PSC disease, since they were found in similar numbers both in cirrhotic and non-cirrhotic 
livers. In our study we saw that Kupffer cells were more intensely stained in the patients than 
in controls, while the frequencies of them were similar. In contrast to T cells, Kupffer cells 
localized in a scattered manner throughout the parenchyma and not only to fibrotic fields.  
 
Monocytes that migrate to sites of injury differentiate into macrophages with different 
phenotypes, as a response to local cytokines in the environment. Immunosuppressive 
interleukins (ILs), such as IL-10, IL-4 and IL-13 are known to induce the alternative 
activation of macrophages into the M2 phenotype, while pro-inflammatory mediators, such as 
IFN-γ, lead to the classical activation into M1 macrophages (76). M2 macrophages are 
associated with suppression of adaptive immune responses, and therefore, they have been the 
focus of several cancer studies (94). We used CD163 as a phenotypic marker for Kupffer 
cells. It should be mentioned that CD163 positive cells might represent the population of M2 
macrophages, reported to be involved in wound healing and anti-inflammatory activities (95). 
Future investigations should include CD68 as a phenotypic marker for characterization and 
localization of the pro-inflammatory M1 subset of macrophages in PSC.  
 
NK cells were observed to localize throughout the parenchyma, but were at similar levels in 
patients and controls. Except for a study conducted in the 1990ies (96), little is known about 
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NK cells and a possible involvement in PSC. Experimental studies using murine models, 
have suggested them to participate in anti-fibrotic activities (97) and therefore it is not 
unlikely to suspect them to be involved in the pathogenesis of PSC. Interestingly, although 
the quantification showed similar levels of NK cells in patients and controls, the PCA 
analysis revealed NKp46 as a phenotypic factor that distinguished PSC patients with mild 
from severe fibrosis. 
 
PCA is a mathematical method, with which multivariate datasets can be visualized as 
completely as possible, with as few graphable dimensions as possible. More specifically, a 
PCA analysis detects new variables (principal components), which account for the vast 
variability in the data set. By doing so, hidden structures in a complex data set can be 
revealed, while noise is filtered out (98). In a first PCA analysis, we aimed to identify 
phenotypic markers that most strongly separated all PSC patients from controls. Therefore, 
histological scores were excluded. Not unexpectedly, the biliary epithelial markers CK7, 
CK19 and EpCAM were all identified as phenotypic markers that separated PSC patients 
from controls.  
 
In a second analysis, the purpose was to find phenotypic factors that separated PSC patients 
according to inflammation, fibrosis and bile duct proliferation. Therefore, the histological 
assessments were included in this analysis. In addition to the identification of NKp46 as a 
factor that distinguished patients according to mild and severe fibrosis, Caldesmon was 
revealed as a marker that separated patients according to mild or severe bile duct 
proliferation. 
 
Caldesmon is a protein involved in contractile functions of smooth muscle cells in the liver 
and in other organs, but it is also reported to participate in cellular processes, such as division, 
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migration, apoptosis etc. (99). Interestingly, some of the PSC patients were observed to have 
a lost expression of Caldesmon, and this was further associated with an increased bile duct 
proliferation and higher numbers of T cells. It is currently unclear why some PSC patients 
lose Caldesmon expression and the eventual effects of it in terms of liver physiology. The 
reduced expression might be a response to inflammation, wound healing or cellular reactions 
that leads to bile duct proliferation. However, the increased T cell infiltration observed in 
patients with lost Caldesmon expression, indicate that their liver disease is more active than 
in patients with normal levels of Caldesmon expression.  
 
Genetic susceptibility within the HLA-region has been reported many times in PSC, but few 
studies have investigated expression at the protein level. In the present study we stained and 
measured the surface expression of MHC class I in PSC patients and controls and found that 
the patients had significantly lower expression. This was further supported by the PCA 
analysis, which revealed MHC class I as a factor that separated the patients from controls. 
Conflicting results have been reported regarding the usefulness of ursodeoxycholic acid 
(UDCA) in the treatment of PSC. Interestingly, in a study where PBC-patients were treated 
with UDCA, the MHC class I expression was observed to be reduced in hepatocytes (100). 
More detailed investigations showed that IFN-γ, which under normal circumstances up-
regulate MHC class I expression, was decreased upon treatment with UDCA (101). In the 
present study, all the PSC patients received UDCA treatment, and consistent with the 
reported finding in PBC, the PSC patients in our study showed a lower MHC class I 
expression than controls.  
 
A limitation of paper II is that the majority of the samples were from patients who underwent 
liver transplantation, that is, patients that had reached end-stage liver disease. Therefore, our 
results probably represent such cellular events that occur during the late stages of the disease, 
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rather than those that occur early. Correlations with clinical parameters should be considered 
with caution, as the number of patients with mild disease was small. Yet another limitation is 
the lack of control samples from individuals with other chronic liver diseases, such as PBC or 
autoimmune hepatitis (AIH). The objective of this study, however, was primarily to 
characterize and localize immune and non-immune cells in PSC livers. The design of it was 
mainly descriptive, and our findings can be viewed as hypothesis generating. Future studies 
of pathogenic mechanisms behind the lost expression of Caldesmon and MHC class I in PSC 
patients, as well as the biology behind specific T cell recruitment to fibrotic fields, will be of 
importance.  
 
PSC patients have an increased risk of developing CCA. The intratumoral composition of 
immune cells has been shown to be important for the ability of cancer cells to establish and 
progress (85). Therefore it is of interest to characterize and quantify cells of immune and non-
immune origin in CCA patient livers. High numbers of Tregs and myeloid-derived suppressor 
cells are associated with a poor prognosis for patients with different cancers (85), whereas 
infiltration of cytotoxic T cells into the tumor area is considered to be more advantageous 
(102).  
 
In paper III we investigated the intrahepatic cellular composition of patients with CCA. We 
studied samples from both within the tumor as well as outside the tumor using 
immunohistochemistry and quantitative image analysis. Histopathological parameters, such 
as tumor location, degree of tumor differentiation or a coexisting PSC disease were examined 
for an eventual impact on the expression of immune cell markers.   
 
The mixture of immune cells within tumors in our study was characterized by a selective loss 
of Kupffer cells and MAIT cells, high numbers of Tregs and a retained cytolytic capability of 
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the CTLs.  Moreover, the expression of IL-33, a cytokine associated with a Th2 cellular 
response, was significantly lower within tumors. This distinct intratumoral phenotype was 
unaffected by tumor location, degree of differentiation, or an underlying PSC. 
 
The liver is an organ that harbors many immune cells, whose activity is controlled by the 
action of immunosuppressive cytokines, such as TGF-β and IL-10 (6). We know little about 
the ability of these immune cells to recognize and combat tumor cells. Little is also known 
about Tregs and their involvement in CCA. The immunosuppressive functions of Tregs has 
been reported in several forms of cancer, and the outcome of their activities depends a lot on 
which cells they are targeted against. In some instances Tregs may suppress the tumor cells, 
which can be beneficial for the host (73). We observed that the Treg specific marker Foxp3 
was significantly increased within tumor areas of CCA patients, which is in line with 
previous reports (74). Moreover, the levels of Tregs were strongly associated with the 
expression of Caldesmon, the phenotypic marker for smooth muscle cells which expression is 
lost in some PSC livers, on which we reported in paper II (103). Caldesmon is involved in 
many cellular processes (104) and at the moment there is no explanation for its association 
with infiltration of Tregs. TGF-beta, which is a cytokine produced by Tregs have previously 
been shown to downregulate the expression of Caldesmon (105). This is contrary to our 
results, which instead showed an increased expression of Caldesmon with increased levels of 
Tregs.  
 
We observed significantly fewer MAIT cells in the tumor areas than in the surrounding, non- 
tumorous tissue. As already mentioned in the discussion of paper II, MAIT cells are T cells 
with an innate phenotype, whose frequencies are reported to be high at mucosal sites in the 
body, including the liver. They have been shown to respond to IL-7, released by hepatocytes 
during inflammation (14), but to date there is no knowledge about an eventual involvement of 
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MAIT cells in cancer. One can speculate on the reason for the observed reduction in tumor 
areas in CCA. One possibility may be that the MR1 molecule, that is required for 
presentation the antigen to MAIT cells, is lost on the tumor cells. Another possibility is that 
MAIT cells are kept outside the tumor area because of the action of immunosuppressive 
cytokines. Since MAIT cells have the ability to immediately exert effector functions against 
bacteria, and given that the liver is constantly exposed to gut-derived microbial compounds, it 
is plausible that MAIT cells may have a role in the pathogenesis of CCA. Further studies will 
be of importance to investigate this.  
 
In addition to the scarce knowledge about MAIT cells in CCA, there are conflicting results on 
the role of cytotoxic T cells in CCA. Earlier studies have reported them to be unchanged or 
reduced in numbers in CCA tumors (74). In the present study, we could not detect any 
significant difference between the total number of CD8+ CTLs outside and inside the tumor 
area. Additionally, their cytolytic functions appeared to be preserved, since the expression of 
perforin was at the same level inside as outside the tumor area.  
 
IL-33 is a cytokine that, in experimental models, has been reported to promote fibrosis (33) as 
well as to drive the malignant transformation of BECs (106). Further support of this is the 
report of increased IL-33 levels in sera and tumors of HCC patients (107). Our results are in 
contradiction to this, as we observed significantly less expression of IL-33 within the CCA 
tumors than in the surrounding, non-tumorous tissue. The majority of the included samples in 
our study were assessed as having mild fibrosis, and it is reasonable to believe that levels of 
IL-33 may increase by severity of fibrosis.  
 
From our earlier report in paper II on an increased number of T cells localizing to fibrotic 
areas in PSC patients (103), we would have expected to see higher numbers of infiltrating 
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immune cells in CCA patients with a coexisting PSC than in CCA patients without PSC. 
However, only small differences were detected. A possible explanation to this is that the 
included PSC patients in paper III were all histologically assessed as having a mild disease, 
except for their cancer, whereas the patients described in paper II mainly consisted of 
individuals with end-stage liver disease. We therefore speculate that the intrahepatic immune 
composition would have looked different if the PSC patients would have had a more severe 
disease.  
 
Furthermore, it was not possible to relate our findings with clinical outcome in paper III, 
since the groups of CCA patients, both with and without PSC were relatively small. Future 
studies should aim to include more samples and use additional techniques, such as flow 
cytometry, for a more detailed phenotypic characterization of the intratumoral compartment 
of CCA. Our data in this study is mainly descriptive, and forthcoming studies should focus in 
revealing mechanisms behind the reduced levels of MAIT cells in CCA tumors, as well as the 
decreased expression of IL-33. This, and more detailed characterization studies, might 
contribute to a better understanding of the pathogenesis of CCA, as well as leading to the 
finding of CCA-specific biomarkers. 
 
 
 
 
 
 
 
 
 
   53 
6 GENERAL CONCLUSIONS 
 
Patients with primary sclerosing cholangitis have circulating IgA and IgG antibodies reactive 
against biliary epithelial cells (paper I).  
 
Autoreactive IgA antibodies in patients with primary sclerosing cholangitis are associated 
with reduced survival (paper I). 
 
The intrahepatic cell composition in patients with primary sclerosing cholangitis is 
heterogeneous but generally characterized by a numerous infiltration of T cells, mainly 
concentrated to the fibrotic areas. Loss of intrahepatic smooth muscle cell markers is 
associated with increased numbers of T cells and a more extensive bile duct proliferation 
(paper II). 
 
Primary sclerosing cholangitis livers have lower expression of MHC class I than controls, 
whereas the levels of NKp46+ NK cells are similar. Instead, NK cells are fewer in numbers in 
severely fibrotic livers as compared to livers with mild fibrosis (paper II).  
 
The tumor microenvironment in livers with cholangiocarcinoma is characterized by high 
numbers of Foxp3+ regulatory T cells and a conserved presence of cytotoxic lymphocytes 
(paper III). 
 
Innate immune cells, such as mucosal-associated invariant T cells and Kupffer cells are 
selectively reduced within cholangiocarcinoma tumors as compared to surrounding tissue 
(paper III).  
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The tumor microenvironment has low expression of the Th2-associated cytokine IL-33. 
These phenotypic characteristics of cholangiocarcinoma tumors are not influenced by tumor 
location, degree of differentiation, or a coexisting primary sclerosing cholangitis (paper III).    
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Primär skleroserande kolangit, PSC, är en ovanlig kronisk leversjukdom som karakteriseras 
av inflammation och ärrbildning (fibros) i gallgångarna. En hög andel av patienterna 
utvecklar med tiden skrumplever. Det finns ett starkt samband mellan PSC och 
inflammatorisk tarmsjukdom, IBD, och i Sverige har drygt 80 procent av alla patienter med 
PSC en samtidig IBD. I Skandinavien förekommer PSC hos drygt 8 av 100 000 individer och 
två tredjedelar av dem som drabbas är män. Det är vanligast att sjukdomen debuterar i yngre 
medelåldern.  
Patienter med PSC har ofta diffusa symptom till en början, som trötthet, klåda, feber och 
högersidig buksmärta. Allt eftersom inflammationen och ärrbildningen fortskrider, förvärras 
de kliniska symptomen till följd av kolestas, som hindrar gallflödet från levern ut till tarmen. 
Den enda botande behandling som finns för patienter med PSC är levertransplantation. Tiden 
från sjukdomsdiagnos fram till att behov för levertransplantation uppstår varierar mellan 12 
och 18 år.  
Förutom risken att utveckla skrumplever och leversvikt, löper patienter med PSC en hög risk 
att utveckla cancer i levern. Särskilt kolangiokarcinom (gallgångscancer) är vanligt 
förekommande och drabbar 10-15 procent av patienterna. En tredjedel av patienterna får sin 
cancerdiagnos inom ett år från det att PSC sjukdomen blivit fastställd. Överlevnaden efter 
diagnos av gallgångscancer är kort, i medeltal mindre än 6 månader. Varför just patienter 
med PSC har så hög risk att utveckla kolangiokarcinom är inte känt, men inflammationen i 
levern är troligtvis en starkt bidragande orsak. 
Etiologin bakom PSC är okänd och det behövs bättre kunskap om de immunologiska 
mekanismer som leder till att sjukdomen utvecklas. PSC uppvisar vissa klassiska egenskaper 
som förknippas med autoimmunitet, så som genetiska variationer inom MHC, eller HLA, 
som det också ofta benämns. MHC regionen är ur immunologiskt perspektiv ett viktigt 
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område i vårt DNA, och innehåller gener som styr vårt immunförsvar. Andra autoimmuna 
egenskaper i PSC är att patienterna ofta har cirkulerande antikroppar i sitt serum, vilka 
reagerar mot kroppsegna proteiner som om de vore främmande ämnen.  
PSC har dock inte alla de egenskaper som räknas som klassiska för en autoimun sjukdom. 
Bland annat så drabbas fler män än kvinnor av PSC, och immunsuppresiv behandling har 
ingen effekt.  
Den kunskap som finns om genetisk känslighet för PSC och som är kopplad både till 
områden inom och utanför HLA regionen, samt observationer om hög invandring av T 
lymfocyter i levern hos PSC patienter, gör att man oftast talar om PSC som en 
immunmedierad sjukdom.  
De leverceller som angrips och förstörs vid den immunmedierade attacken i PSC är 
gallgångscellerna. Biliära epitelceller eller kolangiocyter är andra benämningar för dessa 
celler. Det finns två huvudsakliga hypoteser om varför immunförsvaret aktiveras vid PSC. 
Den ena är att immuncellerna går till attack mot ett antigen av ännu okänt ursprung (t ex 
härstammande från virus, bakterie eller parasit), eller ett autoantigen (kroppseget ämne som 
immunförsvaret uppfattar som främmande). Den andra teorin är att inflammationen 
uppkommer till följd av en känslighet hos de biliära epitelcellerna för gallans toxiska 
sammansättning.  
En av anledningarna till att det är svårt att studera PSC är att patienterna vanligen får sina 
första symptom när sjukdomen pågått under en längre tid. Det är då omöjligt att utröna om de 
immunologiska förändringar som syns i levern vid denna tidpunkt kan sammankopplas med 
den ursprungliga skadan, eller om de är orsakade av sekundära effekter, till följd av den 
kroniska inflammationen. Att för forskningsändamål få tillgång till levervävnad från patienter 
med tidig sjukdom är svårt, och begränsas ytterligare av att PSC är en ovanlig sjukdom. Det 
finns risker med att ta en leverbiopsi och därför görs detta bara i undantagsfall, till exempel 
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för att bättre kunna prognostisera patienten, eller vid misstanke om annan, samtidig 
leversjukdom som går att behandla.  
Att upptäcka tidiga förändringar hos patienter med PSC skulle kunna bidra till identifiering 
av sjukdomsspecifika proteiner, vilket vore värdefullt både ur diagnostiskt och prognostiskt 
hänseende. All forskning som bidrar till att öka förståelsen för de inflammatoriska 
processerna i PSC och varför tumöruppkomst ofta sker, är dock av största vikt för att kunna 
utveckla behandlingsmetoder. 
Det övergripande målet med denna avhandling var att förbättra kunskapen om 
sjukdomsframkallande mekanismer i PSC och den PSC-relaterade cancerformen 
kolangiokarcinom. I de tre studierna har levervävnad från friska kontroller använts för att 
kunna jämföra med prover från PSC patienter. Detta kliniska jämförelsematerial har erhållits 
från patienter som opererat bort en bit av levern på grund av cancer, och där vi då kunnat få 
en bit av den friska vävnaden. I vissa fall har även frisk vävnad erhållits från donerade levrar, 
som på grund av tekniska orsaker inte kunnat användas för transplantation.  
I den första studien har vi undersökt förekomsten av antikroppar i serum från PSC patienter, 
och antikropparnas reaktivitet mot gallgångsceller som vi isolerat från friska, humana levrar. 
Serum som samlats från totalt 81 PSC patienter undersöktes och patienterna kunde följas 
under en sammanlagd tidsperiod av 16 år, från provtagning och fram till att datum för 
dödsfall eller transplantation inföll. Vi fann att en majoritet av patienterna hade antikroppar 
av både IgA och IgG klass, med kapacitet att binda till de isolerade och odlade cellerna. 
Vidare såg vi att patienter med autoreaktiva IgA antikroppar generellt hade högre 
serumnivåer av IgA. Förekomsten av autoreaktiva IgA antikroppar visade sig vara associerat 
med en sämre överlevnad för patienterna. 
 
I studie II har vi med immunhistokemi och kvantitativ bildanalys karakteriserat levervävnad 
från 17 PSC patienter och 17 kontroller. Vi har jämfört levervävnaden med avseende på 
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förekomst och frekvens av olika cellpopulationer, av immunologiskt och icke-immunologiskt 
ursprung. Levervävnaden från PSC patienter erhölls i samband med att patienterna 
genomgick levertransplantation. Vi fann att det fanns stora olikheter inom PSC 
patientgruppen och att vissa fenotypiska mönster var relaterat till svårighetsgrad av sjukdom. 
Sammantaget kännetecknades levrarna från PSC patienter av hög infiltration av T lymfocyter, 
företrädesvis lokaliserad till områden med fibros. Därutöver observerades att levrar med svår 
grad av fibros hade färre NK celler än levrar med mild fibros. Andra fenotypiska skillnader 
som observerades, och som kan tänkas ha betydelse för immunsvaret, var att PSC patienter 
hade lägre uttryckta proteinnivåer av MHC klass I på cellytan.  
I studie III har vi använt samma experimentella och analysbaserade metoder som i studie II, 
men undersökt sammansättningen av immunceller i levervävnad från patienter med 
kolangiokarcinom. Vi har jämfört patienter med kolangiokarcinom, med och utan PSC, men 
vi har även jämfört sammansättningen av celler i tumörområden med hur det såg ut i den 
friska, kringliggande levervävnaden.  
Sammanfattningsvis har studierna visat att autoreaktiva antikroppar finns vid PSC med 
förmåga att binda till biliära epitelceller. Leverinflammationen vid PSC varierar mellan 
individer och kännetecknas framför allt av en massiv T cellsinfiltration, koncentrerad till 
fibros. Tumörområdet i kolangiokarcinom kännetecknas av infiltration av immunsuppressiva 
T celler och ett minskat antal Kupffer och MAIT celler. Dessa fynd utgör en viktig 
kunskapsbas för fortsatta studier av mekanismer som driver den inflammatoriska processen. 
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